Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B: virus, pathogenesis and treatment

P J Grob1

  • 1Department of Medicine, University Hospital, Zurich, Switzerland.

Vaccine
|January 23, 1999
PubMed
Summary

Hepatitis B virus (HBV) features unique immune evasion strategies, leading to variable infection outcomes from self-limited illness to chronic disease and liver cancer. Interferon treatment shows promise but has limitations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered intracellular expression of the chemokines MIP-1alpha, MIP-1beta and IL-8 by peripheral blood CD4+ and CD8+ T cells in mild allergic asthma.

Allergy·2003
Same author

[Hepatitis B virus infection: diagnosis, clinical sequelae, therapy and prevention].

Praxis·2002
Same author

Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.

Journal of acquired immune deficiency syndromes (1999)·2001
Same author

[Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)].

Praxis·2000
Same author

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.

AIDS (London, England)·1999
Same author

Report on Working Group 2: Austria, Belgium, Bulgaria, Germany, Greece, Hungary, Malta, Russia, Switzerland, Turkey and Uzbekistan.

Vaccine·1999

Area of Science:

  • Virology
  • Immunology
  • Hepatology

Background:

  • Hepatitis B virus (HBV) is a DNA virus with unique coat proteins (HBsAg) that induce protective antibodies (anti-HBs) and T-lymphocytes.
  • HBV's non-cytopathogenic nature allows viral survival, but infected cells are targeted by T-lymphocytes via MHC-class I presentation, potentially causing acute hepatitis.
  • Chronic HBV infection can lead to liver cirrhosis and hepatocellular carcinoma, particularly if viral DNA integrates into host DNA.

Purpose of the Study:

  • To explore the outstanding features of Hepatitis B virus (HBV) and their role in the variable course of infection.
  • To understand the mechanisms behind HBV's immune evasion and its impact on disease progression.
  • To review the current treatment options, such as Interferon, and their efficacy and limitations.

Main Methods:

  • Review of viral coat proteins and their immunogenic properties (HBsAg, anti-HBs).
  • Analysis of viral-host interactions, including non-cytopathogenic effects and T-lymphocyte responses.
  • Examination of viral DNA integration and its link to hepatocellular carcinoma.
  • Discussion of factors influencing infection outcomes (immune status, viral load).

Main Results:

  • HBV utilizes HBsAg for humoral immunity and structural proteins for cellular immunity via cytotoxic T-cells.
  • HBV's non-cytopathogenic strategy involves presenting viral peptides on MHC-class I, enabling infected cell detection and elimination, but can lead to acute hepatitis.
  • Chronic infection may involve partial cytopathogenicity and viral DNA integration, increasing hepatocellular carcinoma risk.
  • Self-limited infections occur with efficient early immune response; chronic infections result from weak or absent immunity (e.g., newborns).

Conclusions:

  • HBV's unique biological features dictate the diverse clinical outcomes of infection.
  • Understanding these features is crucial for managing HBV infection and preventing complications like cirrhosis and cancer.
  • Interferon therapy can eliminate HBV in 30-40% of cases but is costly, laborious, and its mechanism requires further elucidation.

Related Experiment Videos